High-Sensitivity Assays for C-reactive Protein as a Systemic Inflammatory Marker in Assessing Asthma

Review No. AR1. BACKGROUND Over the past two decades, new opportunities have emerged in the treatment of severe bronchial asthma due to the development of immunobiological therapy. The effectiveness of biologics depends on correct phenotyping of asthma in patients.1 The Phadiatop test has been known since the 1980s and has established itself as a screening test for the detection of atopy, allergic rhinitis, and allergic asthma.2-9 When selecting patients with severe bronchial asthma for targeted therapy in the Sverdlovsk region, Russia, the PhadiatopTM (Phadia AB, Uppsala, Sweden) screening test was used for phenotyping asthma in this group of patients.